Baricitinib: all 149 studies that test it

Page 1 of 2. Open to participants first (43), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult VolunteersRecruitingNCT07843693Phase 1
• Precision Medicine Adaptive Network Platform Trial in Hypoxemic Acute Respiratory FailureNot yet recruitingNCT07779642Phase 2
• TPO-RA Plus Baricitinib vs. TPO-RA for ITPNot yet recruitingNCT07669675Phase 2
• JAK Signaling in Depression and Cognition in Male Football PlayersRecruitingNCT07608796Phase 2
• Therapeutics for Moderate and Severe DengueNot yet recruitingNCT07543458Phase 3
• Baricitinib for Post-HSCT Persistent ThrombocytopeniaRecruitingNCT07535645Phase 1/2
• Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical TrialNot yet recruitingNCT07449910Phase 2/3
• Baricitinib Effects on Procoagulant State in Rheumatoid ArthritisNot yet recruitingNCT07357649Phase 4
• Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumaticaRecruitingNCT07279688Phase 3
• Biologics in Folliculitis Decalvans : an Adaptative Trial ResearchNot yet recruitingNCT07268534Phase 2
• Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic DermatitisRecruitingNCT07262983Phase 1
• A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)RecruitingNCT07222332Phase 3
• A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and AdultsRecruitingNCT07222137Phase 3
• Baricitinib Curative Repression of HIV-1Not yet recruitingNCT07209267Phase 2
• Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment InterruptionNot yet recruitingNCT07081763Phase 2
• JAK Signaling in DepressionRecruitingNCT07003997Phase 2
• Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological InvolvementRecruitingNCT06923072Phase 2
• A Trial of Baricitinib in Patients With Cardiac SarcoidosisNot yet recruitingNCT06868381Phase 2
• Baricitinib in the Treatment of Intestinal Behçet's SyndromeRecruitingNCT06849908Phase 2
• Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label StudyNot yet recruitingNCT06797310Phase 2
• Vitiligo, New Treatment and Serum s100BRecruitingNCT06768840Phase 2/3
• Baricitinib in CPPD - the BAPTIST StudyNot yet recruitingNCT06768294Phase 2
• JAK Inhibitor Dose TAPering Strategy StudyRecruitingNCT06687551Phase 4
• Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVIDRecruitingNCT06631287Phase 3
• A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular AdenomasRecruitingNCT06490757Phase 2
• Baricitinib for the Lung Injury Following Spontaneous SAHNot yet recruitingNCT06439615Phase 2
• Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialRecruitingNCT06381661Phase 2
• Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With TofacitinibRecruitingNCT06114407Phase 2
• Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/ContusionsRecruitingNCT06065046Phase 2
• Effect of JAK Inhibitor on Erosion Healing in RARecruitingNCT05955066Phase 4
• Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune ThrombocytopeniaRecruitingNCT05932524Phase 2
• "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.Not yet recruitingNCT05914584Phase 2/3
• Inflammation and Depression in People With HIVRecruitingNCT05849038Phase 2
• Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RDRecruitingNCT05781516Not applicable
• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataRecruitingNCT05723198Phase 3
• Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior UveitisNot yet recruitingNCT05651880Phase 3
• Baricitinib for Reduction of HIV - CNSRecruitingNCT05452564Phase 2
• ConsideRAte Study - Splenic Stimulation for RARecruitingNCT05003310Not applicable
• Baricitinib in Patients With Relapsing or naïve DermatomyositisRecruitingNCT04972760Phase 3
• Randomised Evaluation of COVID-19 TherapyRecruitingNCT04381936Phase 3
• A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic ArthritisRecruitingNCT03773965Phase 3
• Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRecruitingNCT03414502Phase 3
• Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingNCT02735707Phase 3
• Baricitinib for the Treatment of Ocular Mucous Membrane PemphigoidTerminatedNCT05263505Phase 2Results posted
• Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket TrialCompletedNCT05189106Phase 1/2Results posted
• Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen PlanusCompletedNCT05188521Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Children With COVID-19TerminatedNCT05074420Phase 3Results posted
• Adaptive COVID-19 Treatment Trial 4 (ACTT-4)CompletedNCT04640168Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGSTerminatedNCT04517253Phase 2/3Results posted
• A Study of Baricitinib (LY3009104) in Participants With COVID-19CompletedNCT04421027Phase 3Results posted
• Adaptive COVID-19 Treatment Trial 2 (ACTT-2)CompletedNCT04401579Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive UveitisActive, not recruitingNCT04088409Phase 3Results posted
• A Study of Baricitinib in Participants With Rheumatoid ArthritisCompletedNCT04086745Phase 4Results posted
• A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic DermatitisCompletedNCT03952559Phase 3Results posted
• JAK Inhibitor Treatment in AGSCompletedNCT03921554Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid ArthritisCompletedNCT03915964Phase 4Results posted
• A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia AreataCompletedNCT03899259Phase 3Results posted
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)TerminatedNCT03843125Phase 3Results posted
• A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic ArthritisCompletedNCT03773978Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCATerminatedNCT03742973Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic DermatitisCompletedNCT03733301Phase 3Results posted
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)CompletedNCT03616964Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus ErythematosusTerminatedNCT03616912Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia AreataCompletedNCT03570749Phase 2/3Results posted
• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic DermatitisTerminatedNCT03559270Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT03435081Phase 3Results posted
• A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically AdvisableCompletedNCT03428100Phase 3Results posted
• A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic DermatitisCompletedNCT03334435Phase 3Results posted
• Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic DermatitisCompletedNCT03334422Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic DermatitisCompletedNCT03334396Phase 3Results posted
• A Study of Baricitinib in Healthy ParticipantsCompletedNCT03212638Phase 1Results posted
• Baricitinib in Relapsing Giant Cell ArteritisCompletedNCT03026504Phase 2Results posted
• Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02759731Phase 1/2Results posted
• A Study of Baricitinib (LY3009104) in Healthy Chinese ParticipantsCompletedNCT02758613Phase 1Results posted
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)CompletedNCT02708095Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT02576938Phase 2Results posted
• A Study to Measure Baricitinib (LY3009104) Absorption in Healthy ParticipantsCompletedNCT02340104Phase 1Results posted
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)CompletedNCT02265705Phase 3Results posted
• A Study of Baricitinib in Healthy Japanese ParticipantsCompletedNCT02263911Phase 1Results posted
• A Study of Baricitinib and Ciclosporin in Healthy ParticipantsCompletedNCT01968057Phase 1Results posted
• A Study of Baricitinib and Simvastatin in Healthy ParticipantsCompletedNCT01960140Phase 1Results posted
• A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy ParticipantsCompletedNCT01924299Phase 1Results posted
• A Study of Baricitinib and Rifampicin in Healthy ParticipantsCompletedNCT01910311Phase 1Results posted
• A Study of Baricitinib and Birth Control Pills in Healthy FemalesCompletedNCT01896726Phase 1Results posted
• An Extension Study in Participants With Moderate to Severe Rheumatoid ArthritisCompletedNCT01885078Phase 3Results posted
• A Pharmacokinetic Study of Baricitinib in Participants With Liver DiseaseCompletedNCT01870388Phase 1Results posted
• A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy ParticipantsCompletedNCT01859078Phase 1Results posted
• A Study in Moderate to Severe Rheumatoid Arthritis ParticipantsCompletedNCT01721057Phase 3Results posted
• A Moderate to Severe Rheumatoid Arthritis StudyCompletedNCT01721044Phase 3Results posted
• A Study in Participants With Moderate to Severe Rheumatoid ArthritisCompletedNCT01711359Phase 3Results posted
• A Study in Moderate to Severe Rheumatoid ArthritisCompletedNCT01710358Phase 3Results posted
• A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney DiseaseCompletedNCT01683409Phase 2Results posted
• A Study of LY3009104 in Healthy ParticipantsCompletedNCT01536951Phase 1Results posted
• A Phase 2b Study of Baricitinib in Participants With Moderate to Severe PsoriasisCompletedNCT01490632Phase 2Results posted
• Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate TherapyCompletedNCT01469013Phase 2Results posted
• A Relative Bioavailability and Food Effect Study of New FormulationsCompletedNCT01398475Phase 1Results posted
• Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human SubjectsCompletedNCT01299285Phase 1Results posted
• A Study of LY3009104(Baricitinib) for Healthy SubjectsCompletedNCT01247350Phase 1Results posted
• A Study in Participants With Rheumatoid Arthritis on Background Methotrexate TherapyCompletedNCT01185353Phase 2Results posted
• INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic DrugsCompletedNCT00902486Phase 2Results posted

← Baricitinib overview